Abstract
We have previously shown that swainsonine, administered systemically to C57BL/6 mice, inhibited the pulmonary metastasis of iv injected B16-F10 melanoma cells by a mechanism involving interleukin-2 production and augmentation of natural killer cell activity. From this finding, which uses an "experimental metastasis" model system, we considered: (a) whether swainsonine would be effective in the inhibition of authentic or spontaneous metastasis; (b) whether the drug would also inhibit metastasis formation in organs other than the lungs; and (c) whether the drug would block the metastasis of tumor cells of different histological type or origin. Our data indicated that swainsonine effectively inhibited the spontaneous metastasis of B16-BL6 melanoma (by 88%) and M5076 reticulum sarcoma (by 95%) murine tumor cells to the lung and liver, respectively. In both cases, the antimetastatic activity of the drug increased as a function of the concentration in drinking water up to 3 micrograms/mL. These findings indicate that the antimetastatic activity of swainsonine is not limited to artificial or experimentally induced metastasis nor to a single tumor type or specific organ. The inhibition of metastasis is likely due to a combination of events, which are currently under investigation.
Original language | English |
---|---|
Pages (from-to) | 1024-8 |
Number of pages | 5 |
Journal | Journal of the National Cancer Institute |
Volume | 81 |
Issue number | 13 |
Publication status | Published - 5 Jul 1989 |
Keywords
- Alkaloids
- Animals
- Antineoplastic Agents
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Liver Neoplasms
- Lung Neoplasms
- Lymphoma, Large B-Cell, Diffuse
- Melanoma, Experimental
- Mice
- Mice, Inbred C57BL
- Neoplasm Metastasis
- Swainsonine
- Tumor Cells, Cultured